The Life Sciences team advised MBX Biosciences on its $34.6 million Series A financing.
MBX is a drug discovery company focused in rare endocrine diseases with substantial unmet medical need. Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets.
The financing was led by Frazier Healthcare Partners, with participation from OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund (IU PhV), Indiana Seed Fund III (managed by BioCrossroads), and Twilight Venture Partners II.
The Goodwin team was led by Mitch Bloom, Kristin Gerber, Dan Hughes, and Matthew Rosencranz.
For more details, read the press release and articles in FierceBiotech, Endpoints, and BioCentury.